As the frontrunners in the race to develop a COVID-19 vaccine begin late-stage trials and sign multi-billion dollar deals to supply the US, European and Japan markets, the commercial picture for this new market is becoming clearer.
Pfizer Inc./BioNTech, Moderna, Inc. and AstraZeneca/Oxford all look capable of gaining an accelerated approval or emergency use authorization...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
